Potentially Inappropriate Sedative-Hypnotic Medication Utilization among Older Adults with Insomnia
Farid Chekani,Saba Zaki,Kirti Mirchandani,Swarnali Goswami,Manvi Sharma,W. Joseph Herring
DOI: https://doi.org/10.1016/j.jagp.2024.01.207
IF: 7.996
2024-02-21
American Journal of Geriatric Psychiatry
Abstract:Introduction Insomnia is a common disorder of aging. However, many sedative-hypnotic medications are considered potentially inappropriate for older adults. This study aimed to describe the utilization of oral sedative-hypnotic medications in elderly individuals with insomnia (EI) and in the subpopulation of patients with Alzheimer's disease and insomnia (ADI) according to published guidelines. Methods A literature review was conducted using a pre-defined search criteria to identify studies related to the treatment guidelines and treatment patterns of insomnia in EI and ADI cohorts. The list of FDA approved oral sedative-hypnotic medications and American Geriatrics Society (AGS) Beers Criteria® were used for the assessment of medication utilization. According to the 2023 update of the AGS Beers Criteria®, atypical antipsychotics (AAPs), z-drugs, and benzodiazepines are potentially inappropriate medications in older adults. Trazodone, one of the most off-label prescribed medications for elderly insomnia was not on the Beers list, and hence it was not included in this study. A cross-sectional analysis was performed to describe the proportion of patients utilizing oral sedative-hypnotic medications in the EI and ADI cohorts, and whether this utilization corresponded with published recommendations. The MarketScan Commercial Claims and Encounters with Medicare Supplemental (2016 -2022) were used to achieve the study objective. All patients aged ≥65 years, with a diagnosis of insomnia and AD were identified using ICD-10 (International Classification of Diseases 10th Revision) codes. The measurement period for assessing utilization of sedative-hypnotic medications was within 365 days after the first diagnosis of insomnia. The following medication classes were included in the analyses: AAPs such as quetiapine and risperidone etc., z-drugs (zopiclone, eszopiclone, zaleplon and zolpidem), benzodiazepines (estazolam, flurazepam, quazepam, temazepam and triazolam), and dual orexin receptor agonists (DORAs) (daridorexant, lemborexant and suvorexant). Results The EI cohort included 695,584 patients. The mean age was 73.12 years and percentage of females was 51.06%. The proportions of patients utilizing the medications were as follows: AAPs (4.25%), z-drugs (11.32%), benzodiazepines (2.48%), and DORAs (0.29%) in EI cohort. In the ADI cohort (n=20,353), the mean age was 83.52 years and percentage of females was 56.83%. The proportions of patients utilizing the medications were as follows: AAPs (28.87%), z-drugs (3.94%), benzodiazepines (2.26%), and DORAs (0.27%) in ADI cohort. Conclusions The utilization of atypical antipsychotics was relatively high among insomnia subpopulation with AD. Although DORAs are not considered as potentially inappropriate medications based on Beers Criteria®, these medications are relatively underutilized in older adults with insomnia. The utilization of approved and appropriate medications for the treatment of insomnia in older adults needs to be prioritized for better management of the condition.
psychiatry,geriatrics & gerontology,gerontology